Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods
暂无分享,去创建一个
Jing Zhang | Yun Tang | Zhejun Xu | Guixia Liu | Guixia Liu | Yun Tang | Jian-xin Cheng | Jing Zhang | Zhejun Xu | Jianxin Cheng
[1] Y. Shimohigashi,et al. Ligand recognition in mu opioid receptor: experimentally based modeling of mu opioid receptor binding sites and their testing by ligand docking. , 1996, Bioorganic & medicinal chemistry.
[2] Jian Li,et al. Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders. , 2004, Journal of medicinal chemistry.
[3] Jiali Gao,et al. Homology Modeling and Molecular Dynamics Simulations of the Mu Opioid Receptor in a Membrane–Aqueous System , 2005, Chembiochem : a European journal of chemical biology.
[4] Mahalaxmi Aburi,et al. Modeling and simulation of the human δ opioid receptor , 2004 .
[5] T. Graczyk,et al. Novel malonamide derivatives as potent κ opioid receptor agonists , 2007 .
[6] C. Dardonville,et al. Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites. , 2004, Bioorganic & medicinal chemistry letters.
[7] Xufeng Sun,et al. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. , 2003, Journal of medicinal chemistry.
[8] J. Cassel,et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. , 1999, The Journal of pharmacology and experimental therapeutics.
[9] Yun Tang,et al. Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists. , 2006, Bioorganic & medicinal chemistry.
[10] K. Rice,et al. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. , 1999, Journal of medicinal chemistry.
[11] Qiang Zhang,et al. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs. , 2005, Journal of molecular graphics & modelling.
[12] W. Greenlee,et al. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. , 2007, Bioorganic & medicinal chemistry letters.
[13] P. Pitis,et al. N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists. , 2004, Bioorganic & medicinal chemistry letters.
[14] R. Shank,et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. , 1995, The Journal of pharmacology and experimental therapeutics.
[15] J. Eisenach,et al. Pharmacology of opioid and nonopioid analgesics in chronic pain states. , 2001, The Journal of pharmacology and experimental therapeutics.
[16] W. Fratta,et al. N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as mu-opioid receptor agonists. Effects on mu-affinity of arylalkenyl chain modifications. , 2002, Bioorganic & medicinal chemistry.
[17] Thierry Langer,et al. Combining Ethnopharmacology and Virtual Screening for Lead Structure Discovery: COX-Inhibitors as Application Example , 2004, J. Chem. Inf. Model..
[18] A. Lomize,et al. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.
[19] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[20] S. Kato,et al. Location of Regions of the Opioid Receptor Involved in Selective Agonist Binding (*) , 1995, The Journal of Biological Chemistry.
[21] Yun Tang,et al. Corrigendum to “Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists” [Bioorg. Med. Chem. 14 (2006) 601–610] , 2006 .
[22] P. Roy,et al. On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .
[23] S. Villa,et al. Synthesis of 3,6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors. , 2006, Bioorganic & medicinal chemistry.
[24] C. Dardonville,et al. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. , 2006, Bioorganic & medicinal chemistry.
[25] G. Chang,et al. An internal-coordinate Monte Carlo method for searching conformational space , 1989 .
[26] A. Beaudet,et al. Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control , 2003, Pain.
[27] B. Wünsch,et al. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies. , 2001, Journal of medicinal chemistry.
[28] C. George,et al. Probes for Narcotic Receptor Mediated Phenomena , 2003 .
[29] U. Holzgrabe,et al. Mechanism of action of the diazabicyclononanone-type kappa-agonists. , 2003, Journal of medicinal chemistry.
[30] Irina D Pogozheva,et al. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. , 2004, Biochemistry.
[31] M. Spetea,et al. Synthesis and Biological Evaluation of 14‐Alkoxymorphinans. Part 19 , 2003 .
[32] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[33] T. Meert,et al. 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists , 2006 .
[34] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[35] W. Greenlee,et al. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. , 2007, Bioorganic & medicinal chemistry letters.
[36] Simona Collina,et al. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity. , 2003, Journal of medicinal chemistry.
[37] G. Uhl,et al. -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.
[38] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[39] M. Aceto,et al. Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic. , 2003, Journal of medicinal chemistry.
[40] J. Deschamps,et al. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. , 2007, Journal of medicinal chemistry.
[41] Marta Filizola,et al. Differentiation of δ, μ, and κ opioid receptor agonists based on pharmacophore development and computed physicochemical properties , 2001, J. Comput. Aided Mol. Des..
[42] G. Pasternak. Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. , 2001, Life sciences.
[43] Weiliang Zhu,et al. Neuraminidase pharmacophore model derived from diverse classes of inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[44] L. Cortes-Burgos,et al. Arylacetamides as peripherally restricted kappa opioid receptor agonists. , 2000, Bioorganic & Medicinal Chemistry Letters.
[45] Xiaodong Zhang,et al. Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide. , 2004, Bioorganic & medicinal chemistry.
[46] Michael Koblish,et al. Novel phenylamino acetamide derivatives as potent and selective κ opioid receptor agonists , 2006 .
[47] Sui-Po Zhang,et al. Identification of potent phenyl imidazoles as opioid receptor agonists. , 2006, Bioorganic & medicinal chemistry letters.
[48] David M. Ferguson,et al. A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist , 2006, J. Comput. Aided Mol. Des..
[49] Cécile Béguin,et al. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). , 2005, Bioorganic & medicinal chemistry letters.
[50] Steven L. Teig,et al. Chemical Function Queries for 3D Database Search , 1994, J. Chem. Inf. Comput. Sci..
[51] E Novellino,et al. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. , 2000, Journal of medicinal chemistry.
[52] Judith L. Flippen-Anderson,et al. Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α-(4-allyl-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]- N-ethyl-N-phenylbenzamide and (-)-4-[(αR)-α-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N -phenylbenzamide , 2003 .
[53] Michael Koblish,et al. Synthesis and evaluation of novel peripherally restricted κ-opioid receptor agonists , 2005 .
[54] P. Pitis,et al. Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists. , 2004, Bioorganic & medicinal chemistry letters.
[55] J. Spudich,et al. Crystal Structure of Sensory Rhodopsin II at 2.4 Angstroms: Insights into Color Tuning and Transducer Interaction , 2001, Science.
[56] Xufeng Sun,et al. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. , 2003, Bioorganic & Medicinal Chemistry Letters.
[57] D. Pagé,et al. New scaffolds in the development of mu opioid-receptor ligands. , 2003, Bioorganic & medicinal chemistry letters.
[58] E. Meng,et al. Rhodopsin Sees the Light , 2000, Science.
[59] T. Steckler,et al. 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective delta-opioid agonists with potential anxiolytic/antidepressant properties. Part 2. , 2007, Bioorganic & medicinal chemistry letters.
[60] G. Pasternak,et al. Ontogeny of opioid pharmacology and receptors: high and low affinity site differences. , 1981, European journal of pharmacology.
[61] S C Basak,et al. A quantitative structure-activity relationship study of N-alkylnorketobemidones and triazinones using structural information content. , 1982, Arzneimittel-Forschung.
[62] T. Hökfelt,et al. Activation of Delta Opioid Receptors Induces Receptor Insertion and Neuropeptide Secretion , 2003, Neuron.
[63] R. Dolle,et al. Peripherally restricted opioid agonists as novel analgesic agents. , 2004, Current pharmaceutical design.
[64] John P. Overington,et al. Derivation of rules for comparative protein modeling from a database of protein structure alignments , 1994, Protein science : a publication of the Protein Society.
[65] D. Tulshian,et al. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.
[66] D. L. Larson,et al. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. , 1998, Journal of medicinal chemistry.
[67] G. Chang,et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .
[68] Yun Tang,et al. QSAR study of 4-phenylpiperidine derivatives as mu opioid agonists by neural network method. , 2006, European journal of medicinal chemistry.
[69] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[70] T. Graczyk,et al. Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. , 2005, Bioorganic & medicinal chemistry letters.
[71] Joshua F. Nitsche,et al. Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice , 1999, Neuron.
[72] S. Collina,et al. Enantiomers of 2-[(Acylamino)ethyl]-1,4-benzodiazepines, potent ligands of kappa-opioid receptor: chiral chromatographic resolution, configurational assignment and biological activity. , 2001, Chirality.
[73] M. Aceto,et al. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. , 2003, Journal of medicinal chemistry.
[74] M. Spetea,et al. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. , 2005, Journal of medicinal chemistry.
[75] Qiong Xie,et al. 3D–QSAR studies of orvinol analogs as κ-opioid agonists , 2006 .